KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Non-Current Deferred Tax Liability: 2020-2025

Historic Non-Current Deferred Tax Liability for AbCellera Biologics (ABCL) over the last 5 years, with Sep 2025 value amounting to $9.7 million.

  • AbCellera Biologics' Non-Current Deferred Tax Liability fell 23.76% to $9.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.7 million, marking a year-over-year decrease of 23.76%. This contributed to the annual value of $10.1 million for FY2024, which is 86.98% down from last year.
  • AbCellera Biologics' Non-Current Deferred Tax Liability amounted to $9.7 million in Q3 2025, which was down 3.07% from $10.1 million recorded in Q2 2025.
  • In the past 5 years, AbCellera Biologics' Non-Current Deferred Tax Liability registered a high of $77.2 million during Q4 2023, and its lowest value of $9.7 million during Q3 2025.
  • For the 3-year period, AbCellera Biologics' Non-Current Deferred Tax Liability averaged around $25.6 million, with its median value being $21.7 million (2024).
  • Per our database at Business Quant, AbCellera Biologics' Non-Current Deferred Tax Liability spiked by 65.54% in 2022 and then plummeted by 86.98% in 2024.
  • AbCellera Biologics' Non-Current Deferred Tax Liability (Quarterly) stood at $37.4 million in 2021, then skyrocketed by 65.54% to $61.9 million in 2022, then rose by 24.65% to $77.2 million in 2023, then slumped by 86.98% to $10.1 million in 2024, then decreased by 23.76% to $9.7 million in 2025.
  • Its Non-Current Deferred Tax Liability was $9.7 million in Q3 2025, compared to $10.1 million in Q2 2025 and $10.1 million in Q1 2025.